Our results suggest that irinotecan was significantly enriched in 14 kinds of cancers and positively correlated with SPA17 in ACC, BLCA, DLBC, GBM, KIRC, KIRP, LUAD, MESO, PCPG, PRAD, SARC, SKCM, TGCT, and especially in DLBC, but only negatively correlated in UVM. Here, SPA17 is linked to bladder transitional cell carcinoma.